209 related articles for article (PubMed ID: 26408743)
1. Detection of Circulating Tumor Cells in Locally Advanced High-risk Prostate Cancer During Neoadjuvant Chemotherapy and Radical Prostatectomy.
Thalgott M; Rack B; Horn T; Heck MM; Eiber M; Kübler H; Retz M; Gschwend JE; Andergassen U; Nawroth R
Anticancer Res; 2015 Oct; 35(10):5679-85. PubMed ID: 26408743
[TBL] [Abstract][Full Text] [Related]
2. Limited prognostic value of preoperative circulating tumor cells for early biochemical recurrence in patients with localized prostate cancer.
Meyer CP; Pantel K; Tennstedt P; Stroelin P; Schlomm T; Heinzer H; Riethdorf S; Steuber T
Urol Oncol; 2016 May; 34(5):235.e11-6. PubMed ID: 26795608
[TBL] [Abstract][Full Text] [Related]
3. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
[TBL] [Abstract][Full Text] [Related]
4. The significance of circulating tumor cells in prostate cancer patients undergoing adjuvant or salvage radiation therapy.
Lowes LE; Lock M; Rodrigues G; D'Souza D; Bauman G; Ahmad B; Venkatesan V; Allan AL; Sexton T
Prostate Cancer Prostatic Dis; 2015 Dec; 18(4):358-64. PubMed ID: 26238233
[TBL] [Abstract][Full Text] [Related]
5. The prevalence and outcomes of pT0 disease after neoadjuvant hormonal therapy and radical prostatectomy in high-risk prostate cancer.
Joung JY; Kim JE; Kim SH; Seo HK; Chung J; Park WS; Hong EK; Lee KH
BMC Urol; 2015 Aug; 15():82. PubMed ID: 26269129
[TBL] [Abstract][Full Text] [Related]
6. Circulating tumor cells as a biomarker predictive of sensitivity to docetaxel chemotherapy in patients with castration-resistant prostate cancer.
Okegawa T; Itaya N; Hara H; Tambo M; Nutahara K
Anticancer Res; 2014 Nov; 34(11):6705-10. PubMed ID: 25368278
[TBL] [Abstract][Full Text] [Related]
7. Circulating tumor cells in newly diagnosed inflammatory breast cancer.
Mego M; Giordano A; De Giorgi U; Masuda H; Hsu L; Giuliano M; Fouad TM; Dawood S; Ueno NT; Valero V; Andreopoulou E; Alvarez RH; Woodward WA; Hortobagyi GN; Cristofanilli M; Reuben JM
Breast Cancer Res; 2015 Jan; 17(1):2. PubMed ID: 25572591
[TBL] [Abstract][Full Text] [Related]
8. Factors affecting recurrence rates after prostatectomy or radiotherapy in localized prostate carcinoma patients with biopsy Gleason score 8 or above.
Kupelian PA; Buchsbaum JC; Elshaikh M; Reddy CA; Zippe C; Klein EA
Cancer; 2002 Dec; 95(11):2302-7. PubMed ID: 12436435
[TBL] [Abstract][Full Text] [Related]
9. Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer.
Thalgott M; Horn T; Heck MM; Maurer T; Eiber M; Retz M; Autenrieth M; Herkommer K; Krause BJ; Gschwend JE; Treiber U; Kübler HR
J Hematol Oncol; 2014 Mar; 7():20. PubMed ID: 24598155
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of disseminated tumor cells in the bone marrow of prostate cancer patients treated with neoadjuvant hormone treatment.
Köllermann J; Weikert S; Schostak M; Kempkensteffen C; Kleinschmidt K; Rau T; Pantel K
J Clin Oncol; 2008 Oct; 26(30):4928-33. PubMed ID: 18794550
[TBL] [Abstract][Full Text] [Related]
11. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
[TBL] [Abstract][Full Text] [Related]
12. Early salvage radiation therapy combined with short-term hormonal therapy in recurrent prostate cancer after radical prostatectomy: single-institution 4-year data on outcome, toxicity, health-related quality of life and co-morbidities from 184 consecutive patients treated with 70 Gy.
Cortés-González JR; Castellanos E; Sandberg K; Eriksson MH; Wiklund P; Carlsson S; Cohn-Cedermark G; Harmenberg U; Gustafsson O; Levitt SH; Lennernäs B; Brandberg Y; Márquez M; Kälkner KM; Nilsson S
Int J Oncol; 2013 Jan; 42(1):109-17. PubMed ID: 23151842
[TBL] [Abstract][Full Text] [Related]
13. Long-term follow-up of a neoadjuvant chemohormonal taxane-based phase II trial before radical prostatectomy in patients with non-metastatic high-risk prostate cancer.
Prayer-Galetti T; Sacco E; Pagano F; Gardiman M; Cisternino A; Betto G; Sperandio P
BJU Int; 2007 Aug; 100(2):274-80. PubMed ID: 17355369
[TBL] [Abstract][Full Text] [Related]
14. Positive surgical margins after radical prostatectomy: do they have an impact on biochemical or clinical progression?
Pfitzenmaier J; Pahernik S; Tremmel T; Haferkamp A; Buse S; Hohenfellner M
BJU Int; 2008 Nov; 102(10):1413-8. PubMed ID: 18537951
[TBL] [Abstract][Full Text] [Related]
15. Circulating Tumor Cells After Neoadjuvant Chemotherapy in Stage I-III Triple-Negative Breast Cancer.
Hall C; Karhade M; Laubacher B; Anderson A; Kuerer H; DeSynder S; Lucci A
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S552-8. PubMed ID: 25968619
[TBL] [Abstract][Full Text] [Related]
16. Long-term follow-up of a prospective trial of trimodality therapy of weekly paclitaxel, radiation, and androgen deprivation in high-risk prostate cancer with or without prior prostatectomy.
Hussain A; Wu Y; Mirmiran A; DiBiase S; Goloubeva O; Bridges B; Mannuel H; Engstrom C; Dawson N; Amin P; Kwok Y
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):167-74. PubMed ID: 21036487
[TBL] [Abstract][Full Text] [Related]
17. Androgen deprivation and high-dose radiotherapy for oligometastatic prostate cancer patients with less than five regional and/or distant metastases.
Schick U; Jorcano S; Nouet P; Rouzaud M; Vees H; Zilli T; Ratib O; Weber DC; Miralbell R
Acta Oncol; 2013 Nov; 52(8):1622-8. PubMed ID: 23544357
[TBL] [Abstract][Full Text] [Related]
18. Pathological and biochemical outcomes after radical prostatectomy in men with low-risk prostate cancer meeting the Prostate Cancer International: Active Surveillance criteria.
Mitsuzuka K; Narita S; Koie T; Kaiho Y; Tsuchiya N; Yoneyama T; Kakoi N; Kawamura S; Tochigi T; Habuchi T; Ohyama C; Arai Y
BJU Int; 2013 May; 111(6):914-20. PubMed ID: 23320782
[TBL] [Abstract][Full Text] [Related]
19. Assessment of circulating tumor cells (CTCs) in prostate cancer patients with low-volume tumors.
Ali A; Furusato B; Ts'o PO; Lum ZP; Elsamanoudi S; Mohamed A; Srivastava S; Moul JW; Brassell SA; Sesterhenn IA; McLeod DG
Pathol Int; 2010 Oct; 60(10):667-72. PubMed ID: 20846264
[TBL] [Abstract][Full Text] [Related]
20. Circulating Tumor Cells in Biochemical Recurrence of Prostate Cancer.
Aragon-Ching JB; Siegel RS; Frazier H; Andrawis R; Hendricks F; Phillips M; Jarrett T; Guebre-Xabiher H; Patierno S; Simmens SJ
Clin Genitourin Cancer; 2015 Oct; 13(5):e341-5. PubMed ID: 25956468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
